There are also two other CDK 4/6 inhibitors currently under investigation: abemaciclib and LEE011, both in phase III trials.
Dr. Swain has received research funding from Genentech, Pfizer, Puma Biotechnology, and Roche. She has also acted as an advisor or consultant and served as a steering committee member for Genentech and Roche, uncompensated. She has received honoraria from Genentech/Roche and Clinigen. She has received travel funding from Genentech.